Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8379158 | 1.00 | SOAT1 (0.44) | SOAT1ALDH1A1TSHRFASNCNR2 | |
| SCHEMBL31141183 | 1.00 | SOAT1 (0.44) | SOAT1ALDH1A1TSHRFASNCNR2 | |
| SCHEMBL27211761 | 0.98 | SOAT1 (0.43) | SOAT1ALDH1A1TSHRFASNCNR2 | |
| SCHEMBL27230059 | 0.98 | SOAT1 (0.43) | SOAT1ALDH1A1TSHRFASNCNR2 | |
| SCHEMBL30885100 | 0.98 | SOAT1 (0.43) | SOAT1ALDH1A1TSHRFASNCNR2 | |
| SCHEMBL27211893 | 0.98 | SOAT1 (0.43) | SOAT1ALDH1A1TSHRFASNCNR2 | |
| SCHEMBL23931288 | 0.83 | TSHR (0.52) | SOAT1ALDH1A1TSHRFASNFAAH | |
| SCHEMBL23931286 | 0.83 | TSHR (0.52) | SOAT1ALDH1A1TSHRFASNFAAH | |
| SCHEMBL5854795 | 0.82 | ALDH1A1 (0.41) | SOAT1ALDH1A1TSHRPPARGPPARD | |
| SCHEMBL5855398 | 0.82 | ALDH1A1 (0.41) | SOAT1ALDH1A1TSHRPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845273-B2 | Method for producing chlorohydrocarbon having conjugated double bonds | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-12-19 | — | — | US | disclosed |
| US-20140275657-A1 | METHOD FOR PRODUCING CHLOROHYDROCARBON HAVING CONJUGATED DOUBLE BONDS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-09-18 | — | — | US | disclosed |
| US-5916983-A | Biologically active compounds by catalytic olefin metathesis | BEND RESEARCH, INC. (US) | 1999-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275657-A1 | METHOD FOR PRODUCING CHLOROHYDROCARBON HAVING CONJUGATED DOUBLE BONDS | ADH1C, ADH1A, CLTC | SOAT1 137/4885ALDH1A1 47/4885TSHR 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.